Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Veracyte, Inc. (VCYT) AI Forecast

Our AI detected a significant signal for Veracyte, Inc.. Create a free account to see the exact price target.

Free account • 30-day free trial

$VCYT Bullish Signal Full forecast available

Veracyte, Inc. (VCYT) Stock Forecast 2025


Veracyte, Inc. (VCYT) AI Stock Price Forecast & Investment Analysis

Veracyte, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Veracyte, Inc. (VCYT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Veracyte, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on March 10, 2026, 11:00 a.m. (UTC)

Veracyte, Inc. Investment Summary

When evaluating whether Veracyte, Inc. (VCYT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Veracyte, Inc. (VCYT) operates within the Industrial Applications and Services sector, specifically in the Services-Medical Laboratories industry. The company employs approximately 557 people. With a market capitalization of $3 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Veracyte, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Veracyte, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Veracyte, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Veracyte, Inc.

Sign Up Free
Corporate Identity

Veracyte, Inc. (Stock Symbol: VCYT) is a prominent company operating within the Industrial Applications and Services sector, with a specific focus on the Services-Medical Laboratories industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Veracyte, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Veracyte, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Veracyte, Inc....

Unlock Full Company Profile

Get complete details about Veracyte, Inc.

Sign Up Free
Revenue & Growth Analysis

Veracyte, Inc. generates annual revenues of $517 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Veracyte, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Veracyte, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Veracyte, Inc....

Unlock Financial Analysis

Get complete financial metrics for Veracyte, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Veracyte, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Veracyte, Inc. strategically competes in the highly dynamic Services-Medical Laboratories marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Veracyte, Inc. competes within the Industrial Applications and Services sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-7 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Margin & Pricing Power Analysis

The company maintains a 29.0% gross margin reflecting moderate pricing power typical of many manufacturing, retail, or service businesses. While not exceptionally high, these margins provide adequate room for operating expenses and profit generation. Competitive pressures or cost increases could impact profitability if margins compress.

Operating margin of -13.5% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 0.23x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 3.81 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Veracyte, Inc. (VCYT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Veracyte, Inc. stock analysis.

Deep dive into Veracyte, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Veracyte, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Veracyte, Inc.: With a P/E ratio of 40.48, the market highly values future growth prospects.

P/E Ratio 40.48x
P/B Ratio 2.05x
Market Cap $2.69B
EPS $0.35
Book Value/Share $16.50
Revenue/Share $6.52
FCF/Share $-0.26
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Veracyte, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Veracyte, Inc.: An ROE of -4.7% indicates room for improvement in shareholder value creation.

ROE -4.7%
ROA -4.4%
ROIC -4.6%
Gross Margin 29.0%
Operating Margin -13.5%
Net Margin -10.9%
EBT Margin -20.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Veracyte, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Veracyte, Inc.: A current ratio of 3.81 indicates strong liquidity.

Current Ratio 3.81x
Quick Ratio 3.30x
D/E Ratio 0.01x
Financial Leverage 1.08x
Interest Coverage -201.6x
Working Capital $359M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Veracyte, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Veracyte, Inc.: Free cash flow of $-7M indicates cash challenges that need attention.

Free Cash Flow -$7M
Capital Spending -$7M
FCF/Sales -2.6%
CapEx/Sales 2.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Veracyte, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Veracyte, Inc.: An asset turnover of 0.23x suggests room for improvement in asset utilization.

Asset Turnover 0.23x
Receivables Turnover 7.1x
Inventory Turnover 9.2x
Fixed Assets Turnover 8.7x
Days Sales Outstanding 51 days
Days Inventory 40 days
Payables Period 39 days
Cash Conversion Cycle 52 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Veracyte, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Veracyte, Inc.: With annual revenue of $517M, Veracyte, Inc. demonstrates solid business size.

Income Statement
Total Revenue $517M
R&D Expense $69M
SG&A Expense $64M
Cost of Goods Sold $255M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 20%
Cash & Short-term Investments 14%
Total Liabilities 8%
Short-term Debt 0%
Accounts Receivable 4%
Inventory 1%
Dividend & Shareholder Information
Shares Outstanding 79M
Growth Metrics (YoY)
EPS Growth -0.3%

Latest Veracyte, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Veracyte, Inc. (VCYT) stock price and investment outlook.

source: Seeking Alpha

Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2024 Financial Results webcast. At this time, all participants are in a listen-only mode. After the ...

source: Insider Monkey on MSN

Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be ...

More news available

Sign up free to read all 8 news articles and stay updated on market developments.

Sign Up Free to Read More

Veracyte, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Veracyte, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Aclarion, Inc. ACON ██% $3M 0.0x 0.3x
Advanced Biomed Inc. ADVB ██% $7M 1.0x 0.7x
American Shared Hospital Services AMS ██% $14M 5.2x 0.6x
Biodesix Inc BDSX ██% $160M -3.0x 140.7x
Bionexus Gene Lab Corp BGLC ██% $5M x 0.8x
Burning Rock Biotech Ltd BNR ██% $0.00M x 0.0x
Caris Life Sciences, Inc. CAI ██% $5.37B 50.5x 9.3x
Caredx, Inc. CDNA ██% $903M 16.5x 3.0x
Celcuity Inc. CELC ██% $4.91B -4.5x 42.0x
Castle Biosciences Inc CSTL ██% $802M -2110.5x 1.7x
Quest Diagnostics Inc DGX ██% $23.52B 23.7x 3.3x
Exact Sciences Corp EXAS ██% $19.75B -343.6x 8.2x
First Choice Healthcare Solutions, Inc. FCHS ██% $130K x 0.0x
Fulgent Genetics, Inc. FLGT ██% $455M 516.8x 0.4x
Fortrea Holdings Inc. FTRE ██% $915M -6.8x 1.6x
Guardant Health, Inc. GH ██% $11.91B -8.9x 174.5x
Grail, Inc. GRAL ██% $2.01B x 0.9x
Labcorp Holdings Inc. LH ██% $22.17B 25.3x 2.6x
Ludwig Enterprises, Inc. LUDG ██% $6M x x
Mdxhealth Sa MDXH ██% $162M x x
Natera, Inc. NTRA ██% $27.68B -74.2x 16.2x
Capforce Inc. OPGN ██% $242M x 23.8x
Psychemedics Corp PMDI ██% $9M x 1.8x
Personalis, Inc. PSNL ██% $696M -2.3x 2.7x
Radnet, Inc. RDNT ██% $4.49B 462.8x 4.1x
Renalytix Plc RENXF ██% $13M x x
Renalytix Plc RNLXY ██% $511M x 73.4x
Sera Prognostics, Inc. SERA ██% $88M -9.0x 1.1x
Veracyte, Inc. VCYT ██% $2.69B 40.5x 2.1x
Exagen Inc. XGN ██% $74M -5.4x 4.1x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Veracyte, Inc. Stock Forecast

How accurate are Veracyte, Inc. stock predictions?

Our AI model shows a 11% Spearman correlation coefficient for VCYT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Veracyte, Inc. stock price forecasts?

Our analysis considers Veracyte, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Veracyte, Inc. a good investment in 2025?

Based on our AI analysis, Veracyte, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Veracyte, Inc. forecasts updated?

Veracyte, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

My Portfolio

Investment Dashboard

Loading your portfolio...